Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients

Innocenti, F.; Wang, J.; Sibley, Alexander B.; Jiang, Chaoyang; Etheridge, Amy S.; Shen, Frank; Patel, Jaimin; Daniel, Hubert Darius J.; Dees, E. Claire; Howard, M M; Bertagnolli, Monica M.; Rugo, HS; Kindler, Hedy L.; Kelly, William Kevin; Ratain, Mark J.; Kroetz, Deanna L.; Owzar, Kouros; Schneider, Benjamin; Lin, Doug; Quintanilha, Júlia Coelho França

doi:10.1016/s0959-8049(20)31090-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, there has been interest in biomarkers of hypertension risk in VEGF inhibitor therapy. The intronic SNP KCNAB1 rs6770663 was associated with an increased risk of moderate‐to‐severe hypertension in a GWAS of bevacizumab‐treated patients and has been proposed as a risk marker 57 …”

Section: Targeted Therapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomic‐Guided Therapy in Colorectal Cancer

Diasio

Innocenti

Offer

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Approximately 20 drugs have been shown to be effective for the treatment of colorectal cancer (CRC). These drugs are from several classes of agents and include cytotoxic drugs, therapeutics that target cell signaling pathways at the extracellular and/or intracellular levels, and combination therapies that contain multiple targeted agents and/or cytotoxic compounds. Targeted therapeutics can include monoclonal antibodies, fusion proteins, and small molecule drugs. The first introduced into clinical use was 5‐fluorouracil in the early 1960s and remains the foundation for most CRC treatments in both adjuvant therapy and in advanced (metastatic) treatment regimens. As with other cancers, the consideration of biomarkers has the potential to improve CRC therapy through patient stratification. The biomarkers can include germline genetic markers, tumor‐specific genetic markers, immune markers, and other biomarkers that can predict antitumor efficacy or the likelihood of toxicity prior to administration of a specific drug. Consistent with the benefit of considering biomarkers in treatment, many newer targeted therapies are developed and approved simultaneously with a companion diagnostic test to determine efficacy. This review will focus on biomarkers that have demonstrated clinical utility in CRC treatment; however, it is noted that many additional biomarkers have been theorized to contribute to drug response and/or toxicity based on known biological pathways but thus far have not attained widespread use in the clinic. The importance of pretreatment biomarker testing is expected to increase as future drug development will likely continue to focus on the concurrent development of companion diagnostics.

show abstract

Section: Targeted Therapeuticsmentioning

confidence: 99%

“…The intronic SNP KCNAB1 rs6770663 was associated with an increased risk of moderate-to-severe hypertension in a GWAS of bevacizumabtreated patients and has been proposed as a risk marker. 57…”

Section: Reviewmentioning

confidence: 99%